HYPERADRENOCORTICISM is a common endocrinopathy that occurs in middle aged to older dogs, and its clinical signs result from an excess of glucocorticoid (Zerbe 1999) . The condition can arise spontaneously from an adrenal tumour, or more commonly from a tumour of either the anterior or intermediate pituitary lobes, that is, pituitary-dependent hyperadrenocorticism (PDH). Hyperadrenocorticism resulting from the ectopic secretion of adrenocorticotrophic hormone (ACTH) has also recently been described in dogs (Galac and others 2005) . Surgical and medical management protocols for PDH have been described, and hypophysectomy is potentially curative, but the rates of success are largely dependent on the skill and experience of the surgeon (Meij and others 2002) . O,pʹ-dichlorodiphenyldichloroethane (mitotane) is the medicine most frequently used for the medical management of the condition. Mitotane is adrenocorticolytic, and an overdose can lead to temporary or permanent hypo adrenocorticism Belshaw 1988, Den Hertog and others 1999) . Other potential complications include drug intolerance and a relatively high frequency of relapses during treatment (Kintzer and Peterson 1991) . Ketoconazole, an imidazole derivative has also been used effectively in affected dogs (Feldman and others 1990) , but gastritis and acute hepatopathy are potentially serious side-effects. Other medicines with either a central or peripheral action such as cyproheptadine (Stolp and others 1984) , bromocriptine (Rijnberk and others 1988) , aminoglutethimide (Perez and others 2002) and L-deprenyl (Reusch and others 1999) have been used, but their efficacy in dogs has not been established.
4α,5-Epoxy-17β-hydroxy-3-oxo-5α-androstane-2α-carbonitrile (trilostane) is a synthetic steroid that competitively inhibits the 3β-hydroxysteroid dehydrogenase enzyme system that converts pregnenolone to progesterone in the adrenal gland and other tissues (Semple and others 1982) . The blockade of this enzyme system results in a decrease in the synthesis of cortisol, aldosterone and 4-androstenedione, effects that have been recorded in human beings (Komanicky and others 1978) , dogs (Potts and others 1978) , cows (McKenna and others 1978) , sheep (Singh-Asa and others 1982), rats (Potts and others 1978) and guinea pigs (Lambert and others 1984) . Trilostane has been used to treat clinical disorders in human beings (Komanicky and others 1978) , horses (McGowan and Neiger 2003) , cats (Skelly and others 2003 , Boag and others 2004 , Neiger and others 2004 and dogs others 2002, Wenger and others 2004) . In human beings, trilostane has been used to treat hyperadrenocorticism due to adrenal and pituitary tumours (Komanicky and others 1978 , Darling and Fraser 1981 , Dewis and others 1983 , Semple and others 1983 , primary hyperaldosteronism and low renin hypertension (Semple and others 1982) , but its reported efficacy varies (Dewis and others 1983, Semple and others 1983) .
The use of trilostane in dogs with PDH has been described by Neiger and others (2002) , Ruckstuhl and others (2002) , Braddock and others (2003) and Wenger and others (2004) . It appears to be as effective as mitotane in alleviating the clinical signs of hyperadrenocorticism and it is generally well tolerated others 2002, Ruckstuhl and others 2002) . Only eight of the 78 dogs studied by Neiger and others (2002) showed poorly controlled clinical signs after two months of treatment.
The pharmacokinetics of trilostane in dogs are poorly characterised and its duration of action is unknown. There is anecdotal evidence that some dogs with PDH whose clinical signs are poorly controlled by single daily doses respond favourably to more than one dose a day (Ramsey and McGrotty 2001) . Wenger and others (2004) showed that there was a decrease in basal cortisol concentrations and responsiveness to ACTH two to six hours after trilostane was administered to dogs with PDH. However, the basal serum cortisol concentrations and the effects of ACTH stimulation testing on serum cortisol concentrations at different times after the administration of trilostane have not been investigated in dogs. The aim of the first part of the present study was to determine the effects of once daily doses of trilostane on the basal cortisol concentrations of dogs with PDH. The aim of the second part was to compare the results of ACTH stimulation tests applied four and 24 hours after a single daily dose of trilostane in dogs whose clinical signs were controlled either well or poorly. The effects of trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor on basal cortisol concentrations and the results of ACTH stimulation tests in dogs with pituitary-dependent hyperadrenocorticism were investigated. In eight of nine dogs trilostane suppressed the concentration of cortisol below the lower limit of the reference range (<50 nmol/l) for a mean (sd) of 3·5 (2·3) hours during the day, but for no longer than 13 hours. In another 10 dogs, there was a clear difference between the post ACTH cortisol concentrations observed four and 24 hours after the administration of trilostane. Furthermore, in the six dogs whose clinical signs were poorly controlled the post-ACTH concentrations observed four and 24 hours after the administration of trilostane were always higher than the equivalent cortisol concentrations in the four dogs whose clinical signs were controlled. A short duration of drug action may be responsible for the failure of some dogs to respond adequately to once daily trilostane administration.
MATERIALS AND METHODS

Clinical cases
Veterinary Record (2006) 159, [277] [278] [279] [280] [281] tests were carried out as described by Mooney and Peterson (2004) . A diagnosis of hyperadrenocorticism was supported by the demonstration of an abnormally high increase in circulating cortisol concentration (>600 nmol/l) after the administration of ACTH, or by the failure to suppress the cortisol concentration below 40 nmol/l eight hours after the administration of a low-dose of dexamethasone (Mooney and Peterson 2004) . The results of a combination of a LDDS test and a high-dose dexamethasone suppression (HDDS) test, the serum ACTH concentrations and adrenal ultrasonography were used to differentiate between pituitary-dependent and adrenal-dependent hyperadrenocorticism, as described by Hoerauf and Reusch (1995) , Feldman and Nelson (1996) and Gould and others (2001) . Ethical approval for all the procedures was obtained from the local ethics committees acting under guidance from the Home Office.
Endocrine assays
Serum or plasma cortisol concentrations were measured by commercially available solid-phase radioimmunoassay kits (Corti-Cote; ICN, in the first part of the study, Coat-a-Count; DPC, in the second part) that had been validated for use in dogs (Ristic and others 2002 , Javadi and others 2003 , Galac and others 2005 and used in previous studies (Neiger and others 2002) . Blood to measure endogenous ACTH was collected into a cooled EDTA tube on ice, centrifuged immediately at 1500 g for 10 minutes, and the plasma frozen at -20°C until it was sent in a cold pack to Cambridge Specialist Laboratories where it was analysed by an immunoradiometric assay (ACTH IRMA; Nichols Institute) that had been validated for use in dogs (Keller-Wood 1990) . The samples were assayed twice in the same assay to calculate the intra-assay coefficient of variation and they were re-analysed if it was more than 15 per cent.
Effect of trilostane on basal cortisol concentrations (study 1)
The basal cortisol concentrations of the nine dogs were measured every four hours for 24 hours and trilostane was then administered once a day for 10 days at the dosages shown in Table 1 . Each dog was dosed at intervals of 24 hours, but the times of administration for different dogs were not standardised. After the 10 doses the serum cortisol concentrations of the dogs were measured again every four hours for 24 hours. A general linear model was used to assess the effect of the dog and treatment on the cortisol concentrations; dog, treatment and time were fitted in the model with their two-way interaction terms, dog as a random effect. Significance was set at P<0·05.
Effect of time of administration of trilostane on ACTH stimulation tests (study 2)
ACTH stimulation tests were applied to another group of 10 dogs with PDH when they were first diagnosed. Then, after they had received a constant daily dose of trilostane for at least three weeks, ACTH stimulation tests were applied four and 24 hours after their last dose of trilostane. On the basis of a clinical examination and a recent history supplied by the owners, each dog was allocated to one of two groups, 'controlled' or 'poorly controlled' . The dogs were classified as 'controlled' if they showed either no evidence of, or a marked improvement in, the clinical signs attributable to hyperadrenocorticism. Their owners did not measure the dogs' intake of water and food and they were therefore categorised as 'controlled' or 'poorly controlled' on the basis of subjective rather than objective criteria. Four of the dogs were classed as 'controlled' , and the other six as 'poorly controlled' (Table 2 ). An ACTH stimulation test was applied four to six hours after a dose of trilostane and the dogs were sent home or hospitalised overnight, whichever was considered less stressful by the clinician; a second ACTH stimulation test was applied 24 hours after the dose of trilostane. The Mann Whitney U test was used to determine whether there were any significant differences between the post-ACTH cortisol concentrations of the 'controlled' and 'poorly controlled' groups of dogs before their treatment began, and whether there were any significant differences between the doses of trilostane administered to the two groups. Mann Whitney U tests were also used to determine whether there were any differences between the post-ACTH cortisol concentrations four and 24 hours after the administration of trilostane within each group and between the subgroups at both times. Significance was set at P<0·05.
RESULTS
Study 1
The nine dogs (Table 1) were included in the report by Neiger and others (2002) . The mean (sd) daily doe of trilostane was 6·3 (4·5) mg/kg bodyweight. All the dogs had shown some improvement in the clinical signs attributable to hyperadrenocorticism when their basal cortisol concentrations were remeasured 10 days after their treatment with trilostane began. In eight of the dogs the serum cortisol concentrations had decreased to below the lower limit of the reference range (<50 nmol/l) between two and 13 hours after the last dose of trilostane) but remained within or above the reference range (50 to 250 nmol/l for the rest of the day); in dog 2 the basal cortisol concentration decreased to 62 nmol/litre four hours after the dose of trilostane. In five of the dogs the serum cortisol concentrations decreased below the detectable limit of the assay (<5 nmol/l). There were significant differences between the cortisol concentrations of the dogs, and when these were corrected for there was still a significant effect of treatment (P=0·02).
Study 2
There was no significant difference between the mean post-ACTH cortisol concentrations of the 'controlled' and 'poorly controlled' groups of dogs before their treatment with trilostane began (data not shown). In the 'controlled' dogs the post-ACTH cortisol concentrations four to six hours after treatment with trilostane ranged from 6 to 39 nmol/l and after 24 hours they ranged from 126 to 148 nmol/l (Table 2 ). In the 'poorly controlled' dogs the post-ACTH cortisol concentrations four to six hours after treatment ranged from 67 to 319 nmol/l, and after 24 hours from 299 to 794 nmol/l (Table 2 ). There were significant differences between the post-ACTH cortisol concentrations after four and 24 hours within the 'poorly controlled' group (P<0·03) and the 'uncontrolled' group (P<0·008). There were also significant differences between the post-ACTH cortisol concentrations after four and 24 hours when the two groups were compared with each other (P=0·01 at both times). In the 'controlled' group the post-ACTH cor- tisol concentration was less than 40 nmol/l four hours after treatment and less than 149 nmol/l 24 hours after treatment; in the 'poorly controlled' group the post-ACTH cortisol concentration was less than 66 nmol/l four hours after treatment and less than 298 nmol/l 24 hours after treatment. There was no significant difference between the doses of trilostane administered to the two groups.
DISCUSSION
Although only 19 dogs were studied, the consistency of the results allows some conclusions to be drawn. The first part of the present study showed that cortisol production was inhibited by trilostane for only a few hours; the second part showed that after ACTH stimulation serum cortisol concentrations were higher 24 hours after a dose of trilostane than after four hours. This difference was sufficiently marked to be of clinical relevance. The six dogs in which the clinical signs were 'poorly controlled' had markedly higher cortisol concentrations at four and 24 hours after ACTH stimulation than the four in which the clinical signs were 'controlled' . It is therefore possible that the drug's short duration of activity is responsible for the residual clinical signs of hyperadrenocorticism in dogs whose signs are poorly controlled by a daily dose of trilostane. In support of this theory, when four of the dogs whose clinical signs were poorly controlled by a single dose of trilostane were switched to twice daily dosing, the clinical condition of three of them improved and their cortisol responsiveness to ACTH stimulation was reduced after both four and 24 hours. It is possible that the decreases in cortisol concentration in the first study may have been due to normal physiological variations in cortisol secretion, but the consistent, steep declines in the two to four hours after a dose of trilostane observed in eight of the nine dogs suggest that they were probably directly associated with the trilostane treatment. A decline in basal cortisol concentrations following the administration of trilostane has been demonstrated in healthy dogs (Potts and others 1978) , in dogs with PDH (Wenger and others 2004) and in human beings with hyperadrenocorticism (Semple and others 1983) . In dog 2, the basal cortisol concentration did not decrease to below the normal range (50 to 250 nmol/l). Dewis and others (1983) did not observe any decline in basal cortisol concentrations in seven human patients, five of them with pituitary-dependent and two with adrenal-dependent hyperadrenocorticism, after treatment with trilostane, and Semple and others (1982) also observed no decline in basal serum cortisol concentration after the administration of trilostane to healthy human subjects. However, there are differences between the mechanisms of action of trilostane between species and extrapolation from studies in human beings may therefore be inappropriate. In vitro studies on sheep adrenals have shown that trilostane has an additional stimulatory effect on 11β-hydroxy steroiddehydrogenase (which converts cortisol to its inactive metabolite cortisone) that may further decrease adrenal steroid biosynthesis in that species. Trilostane had no effect on 11β-hydroxysteroid dehydrogenase obtained from the adrenals of human beings with either hyperadrenocorticism or primary hyperaldosteronism (Touitou and others 1984) . It is therefore apparent that the pharmacokinetics and mechanisms of action of trilostane in dogs require further study.
It is not clear, either from this study or studies by Neiger and others (2002) and Ruckstuhl and others (2002) , whether the ACTH stimulation test is the best method for monitoring the response to trilostane of dogs with hyperadrenocorticism. It has been derived from its use in dogs receiving mitotane (Kintzer and Peterson 1991, Dunn and others 1995) in which the results of the test can be used to make adjustments to their treatment. Trilostane is a competitive inhibitor of cortisol biosynthesis (Komanicky and others 1978) and, as a result, the stimulatory effects of pharmacological doses of ACTH on cortisol production after a dose of trilostane may increase as the inhibitory effect of the trilostane declines. Even in the four dogs whose clinical signs were well controlled by a single daily dose of trilostane, the post-ACTH serum cortisol concentrations increased significantly between four and 24 hours after the dose of trilostane. In these dogs the trilostane probably still inhibited the production of cortisol sufficiently after 24 hours to prevent the return of clinical signs.
Other possible reasons for the increase in post-ACTH cortisol concentrations observed in all 10 dogs 24 hours after trilostane administration include a diurnal variation in response to the ACTH stimulation test. To the authors' knowledge, such a variation has not been observed in dogs and the design of the study prevented it from being investigated. A further possibility is that the second ACTH stimulation test may have been influenced by a residual corticotrophic effect of the first ACTH injection; however, a significant residual effect is unlikely. All the dogs undergoing ACTH stimulation received 0·25 mg of aqueous ACTH intravenously. In normal dogs receiving the same dose administered intramuscularly a decline in serum cortisol concentrations was observed 90 minutes after the injection (Feldman and Tyrell 1977) . The intramuscular administration of an ACTH gel at a dose of 1 iu/0·45 kg resulted in a more prolonged hypercortisolism than the intravenous administration of the same dose (Breznock and McQueen 1969) . However, even in that study, plasma cortisol concentrations had declined almost to preinjection levels after nine hours. In human beings, plasma cortisol concentrations return to preinjection concentrations four hours after the intramuscular administration of 0·25 (Wood and others 1965) . Given the dose used and the route of administration it is unlikely that a significant corticotrophic effect would have remained 20 hours after the first administration of aqueous synthetic ACTH. Exposure to physical and emotional stimuli that might be expected to be stressful can result in an increase in endogenous cortisol production by dogs (Chastain and others 1986, Van Vonderen and others 1998) . In a study by Van Vonderen and others (1998) the urinary corticoid:creatinine ratio was significantly increased in eight of nine healthy dogs that were hospitalised for 36 hours. It is possible that the stress of hospitalisation could have increased the production of endogenous ACTH and cortisol by the dogs in both parts of this study, and in the first part it could have shortened the duration of action of trilostane. The effects of trilostane as a competitive inhibitor of cortisol biosynthesis could have been overwhelmed by the corticostimulatory effects of an increase in ACTH concentration due to stress. In an effort to minimise stress, the environmental conditions and procedures were the same at both hospital visits.
No study has specifically investigated the effects of physiological stress on ACTH stimulation testing in either healthy dogs or dogs with hyperadrenocorticism. In an effort to minimise stress, three of the 10 animals in the second part of the study were discharged overnight rather than kept in the hospital. All of these dogs had undergone ACTH stimulation testing and hospitalisation in the past, and an element of conditioning may therefore have reduced their stress levels. Furthermore, as other possible influences on ACTH responsiveness should have applied equally to the dogs whose clinical signs were 'controlled' or 'poorly controlled' , the increased responsiveness observed at the 24 hour ACTH stimulation test in the 'poorly controlled' dogs was probably due to the lack of therapeutic efficacy of trilostane at that time.
The six 'poorly controlled' dogs had a significantly higher corticotrophic response to ACTH than the four 'controlled' dogs at four and 24 hours after the dose of trilostane, suggesting that the single daily dose was probably inadequate for them. However, all 10 dogs were receiving the dosage of trilostane recommended by the manufacturers (Arnolds Veterinary Products) and there was no significant difference between the doses of trilostane (in mg/kg bodyweight) administered to the two groups. The 'poorly controlled' dogs were less responsive to ACTH stimulation four hours after the dose of trilostane than after 24 hours, suggesting that the trilostane did suppress the corticotrophic effects of ACTH in these dogs to some extent.
The results of this study show that the duration of action of trilostane, as measured by its ability to suppress basal serum cortisol concentrations, can be considerably shorter than 12 hours in some hyperadrenocorticoid dogs. It is therefore possible that, had the daily dose of trilostane been larger the increased suppressive effects on cortisol production might have resulted in signs of hypoadrenocorticism. As trilostane is a competitive inhibitor of cortisol production, any adverse effects are theoretically transient, but the pharmacokinetics and modes of action of trilostane in dogs have not been fully elucidated and prolonged hypoadrenocorticism after the administration of trilostane to dogs has been reported (Eastwood and others 2003, Chapman and others 2004) . It is also possible that a larger daily dose of trilostane might have resulted in better control of the clinical signs without overt hypoadrenocorticism. The capsule sizes available make it difficult to increase the dose by small amounts, but this possibility requires further investigation.
Increasing the frequency of dosing to twice a day appeared to improve the control of the clinical signs in some of the dogs, but it is possible that a longer period of single daily doses might have eventually controlled the clinical signs in these dogs.
A decline in the corticotrophic response to ACTH has been reported in dogs with clinical signs of hyperadrenocorticism that are responsive to trilostane (Neiger and others 2002 , Ruckstuhl and others 2002 , Eastwood and others 2003 and mitotane (Kintzer and Peterson 1991) . A positive response to mitotane and the control of the clinical signs has been linked to a post-ACTH serum cortisol concentration of less than 105 nmol/l (Dunn and others 1995) or 138 nmol/l (Feldman and Nelson 1996) while on maintenance therapy. In the present study the control of clinical signs was associated with a post-ACTH serum cortisol concentration of less than 40 nmol/l four hours after a treatment and less than 149 nmol/l after 24 hours. A lack of control of clinical signs was associated with a post-ACTH cortisol concentration of more than 66 nmol/l four hours after a treatment and more than 298 nmol/l after 24 hours.
Given the small number of dogs studied, it is not possible to define the magnitude of the post-ACTH stimulation cortisol response that is likely to be associated with the control of clinical signs. The small numbers in each group imply that the results of statistical testing should be considered with caution. However, all the differences observed were in the same direction and the Mann Whitney U test indicated that they were significant. Further studies, with larger numbers of animals whose intakes of water and food are known, are needed to provide objective criteria of the response of dogs to treatment with trilostane. Alternative dosing protocols should also be investigated.
It is clear, however, that the effects of a dose of trilostane on the basal serum cortisol concentrations and the corticotrophic effects of ACTH change with time. Witt and Neiger (2004) also demonstrated that the time elapsed after a dose of trilostane was significantly negatively correlated with the endogenous ACTH concentrations in dogs with PDH. Should the ACTH stimulation test continue to be used to monitor the responsiveness of dogs to trilostane, the timing of the test relative to the dose must be consistent if the results are to be interpreted meaningfully; ACTH stimulation tests applied four and 24 hours after the daily dose may help to determine whether the dogs that are not responding adequately to daily dosing need to be dosed more often.
